HUYA Bioscience International Dr. Mireille Gillings Named Pharma Executive of the Year at the BioPharma Industry Awards 2016

Recognized for Visionary Leadership Within Asia’s Pharmaceutical Industry

San Diego, CA, USA – March 24, 2016HUYA Bioscience International (HUYA) Founder and Executive Chair Mireille Gillings, Ph.D., has been named Pharma Executive of the Year at the BioPharma Industry Awards 2016. Presented in conjunction with the 9th BioPharma Asia Convention 2016.

“The Pharma Executive of the Year award recognizes the contributions made by an individual within Asia’s pharmaceutical industry,” according to the BioPharma Industry Awards’ organizers. “Dr. Gillings has exhibited visionary leadership and shown a commitment to leading and communicating change, building partnerships, portraying business acumen and producing optimal results.”

“On behalf of our entire company, I’d like to offer my warmest congratulations to Mireille on this well-deserved achievement,” said Clem Gingras, HUYA’s Chief Technology Officer & Chief Operating Officer Asia. “This award acknowledges Dr. Mireille Gillings groundbreaking achievements in accelerating development and value creation for China-sourced innovations in worldwide markets.”

The award follows a landmark February 2016 agreement between HUYA and Eisai Co. Ltd, under which Eisai will make upfront and milestone payments to HUYA of up to $280M plus royalties on net sales, which was spearheaded by Dr. Gillings. Eisai acquired from HUYA an exclusive license agreement for HBI‐ 8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, Philippines, Vietnam and Singapore. HBI‐8000 is the first approved oral class I‐selective histone deacetylase (HDAC) inhibitor, now in various stages of development for Non‐Hodgkin’s Lymphoma in Japan and solid tumors involving immuno‐oncology (I-O) therapies in the United States. The agreement with Eisai reinforces HUYA’s vision of leveraging clinical data generated within Asia using, the Tripartite Cooperation Treaty between China, Japan and South Korea to expand into other countries such as Japan and South Korea. Last week from Fudan University, global (X-China) rights for indoleamine dioxygenase (IDO) compounds were added to the I-O platform.

About the BioPharma Industry Awards

The BioPharma Industry Awards recognize organizations and individuals for their significant contributions and achievements in Asia’s burgeoning biologics industry as well as for their passion to better shape the global biopharmaceutical operation value chain. http://www.terrapinn.com/exhibition/bio-asia/C59800.stm.

About HUYA Bioscience International

HUYA Bioscience International is the leader in enabling and accelerating the global development of novel biopharmaceutical product opportunities originating in China. Extensive collaborations are established with Chinese biopharmaceutical, academic and commercial organizations to speed development and value creation in worldwide markets for China‐sourced product candidates. With the largest Chinese compound portfolio covering all therapeutic areas, HUYA has emerged as the partner‐of‐choice for maximizing the value of biopharmaceutical innovation in China. HUYA has offices in the U.S., Japan, South Korea and eight strategic locations across China. With the largest team of scientists working with Chinese innovators, HUYA identifies and advances promising drug candidates globally. HUYA received an Asia‐Pacific Stevie® Award in the Health Products and Services & Pharmaceuticals category, and Dr. Mireille Gillings received the Gold Stevie Award in the Woman of the Year 2015 American Business Award category. For more information, please visit www.huyabio.com .

Contact Details:

Yiota Merianos
HUYA Corporate Communications
+1 858 353 1217
ymerianos@huyabio.com